Partial Neuromuscular Blockade in Acute Respiratory Distress Syndrome

NARecruitingINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

October 1, 2020

Primary Completion Date

December 1, 2026

Study Completion Date

March 1, 2027

Conditions
Respiratory InsufficiencyExtracorporeal Membrane Oxygenation ComplicationNeuromuscular Blockade
Interventions
DRUG

Neuromuscular blockade

Cisatracurium will be infused to achieve esophageal pressure targets and maintain a Riker Sedation-Agitation Scale (SAS) score of 1-2. Additional boluses of cisatracurium will be delivered as required and adjustment of continuous infusion rate. After establishing a sedation and NMB strategy at which safe spontaneous breathing is achieved, we will seek to determine whether these targets can be maintained over a 24-hour period.

Trial Locations (1)

M5G 2N2

RECRUITING

University Health Network, Toronto

All Listed Sponsors
lead

University Health Network, Toronto

OTHER